Ohio

A Dose-Ranging Study of IV BNZ-1

This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or refractory Cutaneous T-cell Lymphoma (CTCL).

UNIVERSITY HOSPITALS OF CLEVELAND

University Hospitals of Cleveland 
Study Coordinator/Melanoma/Lymphoma Coordinator, Department of Dermatology
11100 Euclid Ave., Suite 3100
Cleveland, OH 44106
United States

UNIVERSITY DERMATOLOGY CONSULTANTS, INC.

University Dermatology Consultants, Inc. 
222 Piedmont Avenue Ste 5300
Cincinnati, OH 45219
United States

OHIO STATE COMPREHENSIVE CANCER CENTER

Multimodality Cutaneous Lymphoma Clinic - James Cancer Hospital
480 West 10th Avenue
Columbus, OH 43210
United States

CLEVELAND CLINIC

Cleveland Clinic
9500 Euclid Ave. A61
Cleveland, OH 44195
United States

Safety and Efficacy Study of a Dual Pi3k Delta/Gamma Inhibitor in T-Cell Lymphoma

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.